Axsome Therapeutics (AXSM) Amortizatization of Intangibles (2015 - 2026)
Axsome Therapeutics (AXSM) posted Amortizatization of Intangibles of $679000.0 for Q1 2026, down 34.96% sequentially from $1.0 million in Q4 2025, and up 1.8% YoY from $667000.0 in Q1 2025.
Powered by 
Analysis
Axsome Therapeutics (AXSM) Amortizatization of Intangibles (2015 - 2026) Analysis & Trends
Axsome Therapeutics has reported Amortizatization of Intangibles for 11 years, with the latest figure at $679000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles rose 1.8% year-over-year to $679000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (down 7.91% YoY) and the FY2025 annual result came in at $2.2 million, down 17.2% from the prior year.
- Amortizatization of Intangibles fell to $679000.0 in Q1 2026 per AXSM's latest filing, from $1.0 million in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $1.9 million in Q4 2024 and troughed at $110000.0 in Q1 2024.
- A 5-year average of $549294.1 and a median of $454000.0 in 2023 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2024 and 2025: Amortizatization of Intangibles sank 81.16% in 2024, then soared 506.36% in 2025.
- Over 5 years, Amortizatization of Intangibles stood at $346000.0 in 2022, then soared by 31.21% to $454000.0 in 2023, then soared by 327.97% to $1.9 million in 2024, then slumped by 46.27% to $1.0 million in 2025, then slumped by 34.96% to $679000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $679000.0, $1.0 million, and $684000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Axsome Therapeutics | 10.75 Bn | 10.43 Bn | 204.81 Mn | 1.16 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.16 Mn |
| Mar 31, 2026 | 679,000.00 |
| Dec 31, 2025 | 553,000.00 |
| Sep 30, 2025 | 684,000.00 |
| Jun 30, 2025 | 537,000.00 |
| Mar 31, 2025 | 667,000.00 |
| Dec 31, 2024 | 708,000.00 |
| Sep 30, 2024 | 324,000.00 |
| Jun 30, 2024 | 263,000.00 |
| Mar 31, 2024 | 619,000.00 |
| Dec 31, 2023 | 454,000.00 |
| Sep 30, 2023 | 294,000.00 |
| Jun 30, 2023 | 637,000.00 |
| Mar 31, 2023 | 584,000.00 |
| Dec 31, 2022 | 346,000.00 |
| Sep 30, 2022 | 250,000.00 |
| Jun 30, 2022 | 299,000.00 |
| Mar 31, 2022 | 275,000.00 |
| Dec 31, 2021 | 225,138.00 |
| Sep 30, 2021 | 135,885.00 |